{"schema_version":"secwatch.filing_event.v1","accession":"0001741830-24-000036","form_type":"8-K","ticker":null,"cik":"0001741830","company_name":"Kronos Bio, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.845375+00:00","generated_at":"2026-06-02T06:33:37.671218+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Kronos Bio Q1 net loss $30M, cash $152M into H2 2026; restructuring charges $12.8M","bullets":["Net loss of $30.0M ($0.50/share) includes $7.7M stock-based comp; R&D $14.2M, G&A $7.5M.","Impairment of long-lived assets $6.6M; restructuring expense $6.2M (includes $4.4M stock-based comp).","Cash, equivalents and investments $152.0M, sufficient into second half of 2026.","KB-0742 Phase 1/2 update to be presented at ASCO June 1; expansion cohorts on track Q3 2024.","KB-9558 IND-enabling studies to complete by end 2024; first-in-human expected H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001741830-24-000036","json":"https://secwatch.observer/filing/0001741830-24-000036.json","markdown":"https://secwatch.observer/filing/0001741830-24-000036.md","text":"https://secwatch.observer/filing/0001741830-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1741830/000174183024000036/0001741830-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1741830/000174183024000036/kron-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:33:37.671218+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"39353086e8f38e30869925613f90d7fce5a8b86a","claim":"Kronos Bio, Inc. reported the quarter ended March 31, 2024 results: net income $30.0 million, or $0.50 per share, EPS $0.50 per share.","evidence_excerpt":"Net loss for the first quarter of 2024 was $30.0 million, or $0.50 per share, including non-cash stock-based compensation expense of $7.7 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1741830/000174183024000036/0001741830-24-000036-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$30.0 million, or $0.50 per share"},{"label":"EPS","value":"$0.50 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}